Recent Updates
Recently added Catalysts
MRK Positive Sentiment

Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium

Thursday, October 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Merck and Moderna announced positive results from the Phase 3 INTerpath-001 trial for intismeran autogene. The trial demonstrated significant improvements in recurrence-free survival and distant metastasis-free survival. These findings will be presented at the ESMO 2026 Presidential Symposium, highlighting the potential of this novel mRNA-based therapy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive results in recurrence-free survival reported.
  • Distant metastasis-free survival results are encouraging.
  • Collaboration between Merck and Moderna shows strong potential.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
2.8%
average across 15 past catalysts
Lead asset
MK-8527
Phase 1 · Renal Impairment

Full Press Release Details

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in c

Frequently Asked Questions

What is the INTerpath-001 trial about?

The INTerpath-001 trial evaluates intismeran autogene, an mRNA-based therapy.

What were the key results from the trial?

The trial showed positive recurrence-free and distant metastasis-free survival results.

When will the results be presented?

The results will be presented at the ESMO 2026 Presidential Symposium.

Who developed intismeran autogene?

Intismeran autogene is jointly developed by Merck and Moderna.

ShareAdd on Google
Tags: MRK Merck Moderna intismeran Phase 3 trial ESMO 2026
Last updated: Oct 22, 2026

Biotech snapshot

Cash runway
$8363M liquidity · $0M/mo burn
Low dilution risk
Lead asset
MK-8527Phase 1
Renal Impairment →

Catalyst track record

+37%
best trade around MRK's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for MRK.

See every catalyst's timing & PoA →